{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:07Z","timestamp":1786994407702,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103364","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T11:19:02Z","timestamp":1635765542000},"page":"103364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis"],"prefix":"10.1016","volume":"57","author":[{"given":"A.A.","family":"Toorop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.Y.G.J.","family":"van Lierop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.M.J.","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.L.E.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103364_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102704","article-title":"Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness","volume":"48","author":"Barun","year":"2021","journal-title":"Mult. Scler. Relat Disord"},{"key":"10.1016\/j.msard.2021.103364_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000678","article-title":"Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy","volume":"7","author":"Bringeland","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103364_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102020","article-title":"End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?","volume":"41","author":"Catherine","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103364_bib0021","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2021.103364_bib0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103364_bib0014","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103364_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00365513.2020.1730434","article-title":"Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults","volume":"80","author":"Hviid","year":"2020","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.msard.2021.103364_bib0017","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2021.103364_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103364_bib0015","first-page":"224","article-title":"Prediction of blood volume in normal human adults","volume":"51","author":"Nadler","year":"1962","journal-title":"Surgery"},{"key":"10.1016\/j.msard.2021.103364_bib0020","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458514530489","article-title":"Responder definition of the multiple sclerosis impact scale physical impact subscale for patients with physical worsening","volume":"20","author":"Phillips","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103364_bib0007","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7224\/1537-2073.2013-017","article-title":"Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle","volume":"16","author":"Ratchford","year":"2014","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2021.103364_bib0012","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103364_bib0003","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103364_bib0022","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1352458519853473","article-title":"Obesity worsens central inflammation and disability in multiple sclerosis","volume":"26","author":"Stampanoni Bassi","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103364_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117501","article-title":"Personalizing ocrelizumab treatment in Multiple Sclerosis: what can we learn from Sars-Cov2 pandemic?","volume":"427","author":"Tazza","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103364_bib0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.103364_bib0018","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000904","article-title":"Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab","volume":"8","author":"Toorop","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103364_bib0004","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103364_bib0009","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103364_bib0010","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","author":"van Lierop","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103364_bib0016","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis\u2013establishing disease prognosis and monitoring patients","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:35:45Z","timestamp":1735558545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":22,"alternative-id":["S2211034821006313"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103364","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103364"}}